Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: Case report from the northwestern emergency medicine residency

American Journal of Therapeutics

Volumn 20, Issue 3, 2013, Pages 300-306

  Kiraly, Amy ^a   Lyden, Abbie ^b,c   Periyanayagam, Usha ^a   Chan, Jennifer ^a   Pang, Peter S ^a,d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d Center for Cardiovascular Research   (United States)

^e Institute for Public Health and Medicine   (United States)

Author keywords

Anticoagulation; Dabigatran; Feiba; Hemorrhage; Prothrombin complex concentrates; Rivaroxaban

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9 COMPLEX; COFACT; DABIGATRAN; DABIGATRAN ETEXILATE; FRESH FROZEN PLASMA; KANOKAD; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; PRT 064445; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CASE REPORT; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROCARDIOGRAM; EMBOLISM; EMERGENCY MEDICINE; EMERGENCY WARD; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMOPHILIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUNG EMBOLISM; MALE; MEDICAL HISTORY; MENTAL DISEASE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; THROMBOPLASTIN TIME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANEURYSM, RUPTURED; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; COMBINED MODALITY THERAPY; EMERGENCY SERVICE, HOSPITAL; HEMOPERITONEUM; HEMOSTATIC TECHNIQUES; HUMANS; ILIAC ANEURYSM; MALE; MORPHOLINES; SUBARACHNOID HEMORRHAGE; THIOPHENES; THROMBOEMBOLISM;

EID: 84880071979     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182878d18     Document Type: Article

References (19)

1. Kaatz S, Kouides P, Garcia A, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141-S145.
2. Pradaxa [Online] [package insert]. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT; 2012. Available at: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed January 10, 2013.
3. Xarelto [Online] [package insert]. Janssen Pharmaceuticals Inc, Titusville, NJ; 2012. Available at: http://www.xareltohcp.com/sites/default/ files/pdf/xarelto-0.pdf#zoom5100. Accessed January 10, 2013.
4. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallet-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.
5. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:E152s-E184s.
6. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-876.
7. American Society of Hematology. Clinical practice guide on anticoagulant dosing and management of anticoagulantassociated bleeding complications in adults [Online]. 2011. Available at: http://www.hematology.org/Practice/ Guidelines/2934.aspx.
8. New Zealand Government, Pharmaceutical Management Agency. Guidelines for management of bleeding with dabigatran-for possible inclusion into local management protocols [Online]. 2011. Available at: http://pharmac.govt.nz/2011/ 06/13/Dabigatran%20bleeding%20management.pdf. Accessed January 10, 2013.
9. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
10. Dzik W. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion. 2012;52:45S-55S.
11. FEIBA [Online] [prescribing information]. Baxter Healthcare Corp, Roundlake, IL; 2009. Available at: http://www.feiba.com/pdf/feiba-500-100-u-pi- 0309.pdf.
12. Battinelli E. Reversal of new oral anticoagulants. Circulation. 2011;124:1508-1510.
13. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilatea novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
14. Eerenberg E, Sijpkens M, Meijers J, et al. Response to letters regarding article "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2012;125:e616.
15. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.
16. van Ryn JRD, Priepke H, Hauel N, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate [abstract]. Haematologica. 2008;93:148. Abstract 0370.
17. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.
18. Lu G, Luan P, Hollenbach SJ, et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors [abstract]. J Thromb Haemost. 2009; 7(suppl 2):309-310.
19. Hutchaleelaha A, Lu G, Deguzman F, et al. Recombinant factor Xa inhibitor antidote (PRT064445) mediates reversal of anticoagulation through reduction of free drug concentration: a common mechanism for direct factor Xa inhibitors [abstract supplement]. Eur Heart J. 2012; 33:496.